BEGIN:VCALENDAR VERSION:2.0 PRODID:-//NephU - ECPv6.15.10//NONSGML v1.0//EN CALSCALE:GREGORIAN METHOD:PUBLISH X-WR-CALNAME:NephU X-ORIGINAL-URL:https://nephu.org X-WR-CALDESC:Events for NephU REFRESH-INTERVAL;VALUE=DURATION:PT1H X-Robots-Tag:noindex X-PUBLISHED-TTL:PT1H BEGIN:VTIMEZONE TZID:America/New_York BEGIN:DAYLIGHT TZOFFSETFROM:-0500 TZOFFSETTO:-0400 TZNAME:EDT DTSTART:20210314T070000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:EST DTSTART:20211107T060000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0500 TZOFFSETTO:-0400 TZNAME:EDT DTSTART:20220313T070000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:EST DTSTART:20221106T060000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0500 TZOFFSETTO:-0400 TZNAME:EDT DTSTART:20230312T070000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:EST DTSTART:20231105T060000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0500 TZOFFSETTO:-0400 TZNAME:EDT DTSTART:20240310T070000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:EST DTSTART:20241103T060000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0500 TZOFFSETTO:-0400 TZNAME:EDT DTSTART:20250309T070000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:EST DTSTART:20251102T060000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0500 TZOFFSETTO:-0400 TZNAME:EDT DTSTART:20260308T070000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:EST DTSTART:20261101T060000 END:STANDARD END:VTIMEZONE BEGIN:VTIMEZONE TZID:America/Chicago BEGIN:DAYLIGHT TZOFFSETFROM:-0600 TZOFFSETTO:-0500 TZNAME:CDT DTSTART:20240310T080000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0500 TZOFFSETTO:-0600 TZNAME:CST DTSTART:20241103T070000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0600 TZOFFSETTO:-0500 TZNAME:CDT DTSTART:20250309T080000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0500 TZOFFSETTO:-0600 TZNAME:CST DTSTART:20251102T070000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0600 TZOFFSETTO:-0500 TZNAME:CDT DTSTART:20260308T080000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0500 TZOFFSETTO:-0600 TZNAME:CST DTSTART:20261101T070000 END:STANDARD END:VTIMEZONE BEGIN:VTIMEZONE TZID:America/Los_Angeles BEGIN:DAYLIGHT TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT DTSTART:20210314T100000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST DTSTART:20211107T090000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT DTSTART:20220313T100000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST DTSTART:20221106T090000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT DTSTART:20230312T100000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST DTSTART:20231105T090000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT DTSTART:20240310T100000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST DTSTART:20241103T090000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT DTSTART:20250309T100000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST DTSTART:20251102T090000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT DTSTART:20260308T100000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST DTSTART:20261101T090000 END:STANDARD END:VTIMEZONE BEGIN:VTIMEZONE TZID:America/North_Dakota/New_Salem BEGIN:DAYLIGHT TZOFFSETFROM:-0600 TZOFFSETTO:-0500 TZNAME:CDT DTSTART:20230312T080000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0500 TZOFFSETTO:-0600 TZNAME:CST DTSTART:20231105T070000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0600 TZOFFSETTO:-0500 TZNAME:CDT DTSTART:20240310T080000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0500 TZOFFSETTO:-0600 TZNAME:CST DTSTART:20241103T070000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0600 TZOFFSETTO:-0500 TZNAME:CDT DTSTART:20250309T080000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0500 TZOFFSETTO:-0600 TZNAME:CST DTSTART:20251102T070000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0600 TZOFFSETTO:-0500 TZNAME:CDT DTSTART:20260308T080000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0500 TZOFFSETTO:-0600 TZNAME:CST DTSTART:20261101T070000 END:STANDARD END:VTIMEZONE BEGIN:VTIMEZONE TZID:America/Denver BEGIN:DAYLIGHT TZOFFSETFROM:-0700 TZOFFSETTO:-0600 TZNAME:MDT DTSTART:20210314T090000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0600 TZOFFSETTO:-0700 TZNAME:MST DTSTART:20211107T080000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0700 TZOFFSETTO:-0600 TZNAME:MDT DTSTART:20220313T090000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0600 TZOFFSETTO:-0700 TZNAME:MST DTSTART:20221106T080000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0700 TZOFFSETTO:-0600 TZNAME:MDT DTSTART:20230312T090000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0600 TZOFFSETTO:-0700 TZNAME:MST DTSTART:20231105T080000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0700 TZOFFSETTO:-0600 TZNAME:MDT DTSTART:20240310T090000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0600 TZOFFSETTO:-0700 TZNAME:MST DTSTART:20241103T080000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0700 TZOFFSETTO:-0600 TZNAME:MDT DTSTART:20250309T090000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0600 TZOFFSETTO:-0700 TZNAME:MST DTSTART:20251102T080000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0700 TZOFFSETTO:-0600 TZNAME:MDT DTSTART:20260308T090000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0600 TZOFFSETTO:-0700 TZNAME:MST DTSTART:20261101T080000 END:STANDARD END:VTIMEZONE BEGIN:VTIMEZONE TZID:America/Barbados BEGIN:STANDARD TZOFFSETFROM:-0400 TZOFFSETTO:-0400 TZNAME:AST DTSTART:20220101T000000 END:STANDARD END:VTIMEZONE BEGIN:VTIMEZONE TZID:America/Mexico_City BEGIN:DAYLIGHT TZOFFSETFROM:-0600 TZOFFSETTO:-0500 TZNAME:CDT DTSTART:20220403T080000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0500 TZOFFSETTO:-0600 TZNAME:CST DTSTART:20221030T070000 END:STANDARD END:VTIMEZONE BEGIN:VTIMEZONE TZID:America/Phoenix BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0700 TZNAME:MST DTSTART:20210101T000000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTART;TZID=America/New_York:20250916T183000 DTEND;TZID=America/New_York:20250916T203000 DTSTAMP:20260718T113030 CREATED:20250828T191303Z LAST-MODIFIED:20250828T191308Z UID:10001018-1758047400-1758054600@nephu.org SUMMARY:4 Part IgAN Experience DESCRIPTION:About This Event\n \n \n \n \n \n \n \n \n \n \n IgA Nephropathy: Early Signs & Symptoms\, Disease Burden\, & Management\n 1. IgA Nephropathy:  Early Signs and Symptoms\, Disease Burden\, and Management\nDuring this presentation you will learn the clinical presentation\, diagnosis\, prognosis\, and unmet treatment needs of IgAN. You will then take a deep dive into the current understanding of IgAN pathogenesis including the four hit cascade and the key role B-cells and APRIL (A PRoliferation-Inducing Ligand) play in driving disease progression.\n2. IgAN Simulator\nHere you can get an in-depth look at IgAN pathogenesis and the journeys of patients living with IgAN.\n\n Pathogenesis: See the origins of IgAN at the molecular level and how that results in its progression\n Progression: Journey into the profiles of 3 hypothetical patients to see how their IgAN diagnosis was uncovered\, and what’s expected in their prognosis\n\n3. Apple Vision Pro Immersive Experience\nExperience disease-state education like never before. Using Apple Vision Pro technology\, participants can visually explore:\n\n The 4-hit pathogenic process of IgAN\n The role of APRIL in initiating and sustaining kidney injury in IgAN\n\n4. NephU Resource Station\n\n Check out our educational infographics and grab printed copies to take with you\n Learn about our educational tools and treatment summaries\n \n \n\n\n\n\n\n\n \n Location\n \n \n\n\n\n\n\n\n\n\nFeaturing\n\n\n\n \n \n \n Kimberly Means\, PharmD\, BCCCP\, BSN\, RN\n Medical Science Liaison\n \n \n \n \n \nOtsuka Pharmaceutical Development & Commercialization\, Inc.*\n \n \n Kimberly Means\, PharmD\, BCCCP\, BSN\, RN\, is a Medical Science Liaison at Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC).  Dr Means earned her B.S. in Nursing (BSN) and her Doctor of Pharmacy (PharmD) from Virginia Commonwealth University (VCU) in Richmond\, Virginia.  She completed a PGY-1 Pharmacy Practice Residency and a PGY-2 Critical Care Residency at VCU Health in Richmond\, Virginia.  Prior to joining Otsuka\, she worked as a critical care nurse at VCU Health\, a Critical Care Clinical Pharmacist at Henrico Doctors’ Hospital\, and a Clinical Pharmacist in Surgical Services at VCU Health.  During her time as a Clinical Assistant Professor at the VCU School of Pharmacy and VCU Health she served as a preceptor for pharmacy students and pharmacy residents.  Dr Means is a Board Certified Critical Care Pharmacotherapy Specialist (BCCCP). \n\n \n \n\n\n \n \n \n Michael Filsinger\, MPA\, PA-C\n Nephrology Medical Science Liaison\n \n \n \n \n \nOtsuka Pharmaceutical Development & Commercialization\, Inc.*\n \n \n Michael Filsinger\, MPA\, PA-C is a Medical Science Liaison at Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC). Michael earned his Bachelor of Health Care Sciences as well as Master of Physician Assistant at Duquesne University in Pittsburgh\, PA. Following his graduate training\, Michael went on to complete a Pediatric Surgery Residency at Children’s National Medical Center in Washington\, DC Prior to joining Otsuka\, Michael spent the last 15 years working in solid organ transplant in Charlotte\, NC where he developed a passion for improving the care of patients with renal disease and ESKD. \n\n \n \n\n\nKimberly Means\, PharmD\, BCCCP\, BSN\, RN and Michael Filsinger\, MPA\, PA-C are employees of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n \n Registration URL:https://nephu.org/event/4-part-igan-experience-2/ LOCATION:Aberdeen Barn Steakhouse\, 5805 Northampton Blvd\, Virginia Beach\, VA\, 23455\, United States CATEGORIES:Live Event ATTACH;FMTTYPE=image/jpeg:https://nephu.org/wp-content/uploads/2022/12/IgAN-Overview-podcast_resize.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Chicago:20250814T180000 DTEND;TZID=America/Chicago:20250814T200000 DTSTAMP:20260718T113030 CREATED:20250717T204438Z LAST-MODIFIED:20250721T171632Z UID:10001014-1755194400-1755201600@nephu.org SUMMARY:IgA Nephropathy: Pathogenesis\, the Role of APRIL and the 4-Hit Process\, and a Patient Case Study DESCRIPTION:About This Event\n \n \n \n \n \n \n \n \n \n \n IgA Nephropathy: Early Signs & Symptoms\, Disease Burden\, & Management\n IgA Nephropathy: Pathogenesis\, the Role of APRIL and the 4-Hit Process\, and a Patient Case Study – Edgar Lerma\, MD\n\n \n\n Program Objectives:\n\n The disease burden and current treatment landscape in IgA Nephropathy\n Risk factors associated with disease progression in a patient case study\n The four-hit process in IgA nephropathy pathogenesis and the role of APRIL\n\n\n\n\n\n \n\nIgAN Simulator – Molly Jansen (MSL)\n\n \n\n Here you can get an in-depth look at IgAN pathogenesis and the journeys of patients living with IgAN\n\n Pathogenesis: See the origins of IgAN at the molecular level and how that result sin its progression\n Progression: Journey into the profiles of 3 hypothetical patients to see how their IgAN diagnosis was uncovered\, and what’s expected in their prognosis\n\n\n\n\n\n \n\nApple Vision Pro Immersive Experience – Michael Filsinger (MSL)\n\n \n\n Experience disease state education like never before. Using Apple Vision Pro technology\, participants can visually explore:\n\n The 4-hit pathogenic progress of IgAN\n The role of APRIL in initiating and sustaining kidney injury in IgAN\n\n\n\n\n\n \n\nNephU Resource Station – Molly Jansen (MSL)\n\n \n\n Check out our educational infographics and grab printed copies to take with you\n Learn about our educational tools and treatment summaries\n\n\n \n \n\n\n\n\n\n\n \n Location\n \n \n\n\n\n\n\n\n\n\nFeaturing\n\n\n\n \n \n \n Edgar Lerma\, MD\n Clinical Professor of Medicine\, Section of Nephrology\, University of Illinois at Chicago\n \n \n \n \n University of Illinois at Chicago* \n \n Edgar Lerma\, MD\, earned his Doctor of Medicine from the University of Santo Tomas Faculty of Medicine and Surgery in Manila\, Philippines. He completed Residency Training in Internal Medicine at UIC/Mercy Hospital and Medical Center\, where he also served as Chief Resident. He completed a Fellowship in Nephrology and Hypertension at Northwestern Memorial Hospital\, the Feinberg School of Medicine at Northwestern University\, and the Veterans Administration Lakeside Medical Center in Chicago\, Illinois. \nDr Lerma is a Diplomate in the Subspecialty of Nephrology with the American Board of Internal Medicine. He has authored more than 100 peer-reviewed publications and presentations; notable publications include Current Diagnosis & Treatment: Nephrology & Hypertension\, Nephrology Secrets\, and Henrich’s Principles and Practice of Dialysis. He has peer reviewed and served on editorial boards for numerous journals\, and currently is Associate Editor for International Urology and Nephrology\, Clinical Reviews in Bone and Mineral Metabolism\, and Journal of Clinical Lipidology. \nAt present\, he holds the rank of Clinical Professor of Medicine with the Section of Nephrology at University of Illinois at Chicago. He serves as the Educational Coordinator for Nephrology with UIC/Advocate Christ Medical Center. \nIn recognition of his clinical work and expertise\, Dr Lerma has been elected to Fellowship of the American College of Physicians\, Fellowship of the American Society of Nephrology\, Fellowship of the American Heart Association/ Council on Kidney in Cardiovascular Disease\, Fellowship of the American Society of Hypertension\, Fellowship of the National Lipid Association\, Fellowship of the National Kidney Foundation\, and Fellowship of the American Society of Diagnostic and Interventional Nephrology. He has also been recognized for teaching and has been the recipient of “Subspecialty Teaching Attending Physician of the Year” in 2006 and “Physician Recognition Award for Excellence in Academics” in 2011 from UIC/Advocate Christ Medical Center Internal Medicine Residency Training Program. \nDr Lerma’s research interests include CKD\, hypertension\, bone and mineral disorders\, and dyslipidemias in CKD. \n\n \n \n\n\n \n \n \n Molly Jansen\, PhD\n Nephrology Senior Medical Science Liaison\n \n \n \n \n Otsuka Pharmaceutical Development & Commercialization\, Inc.*\n \n Dr Molly Jansen is a Nephrology Medical Science Liaison at Otsuka Pharmaceutical Development & Commercialization\, Inc. covering South Texas. Molly earned her Doctor of Philosophy degree in Biomedical Science from Wake Forest School of Medicine located in Winston-Salem\, NC. While in graduate school\, Molly worked as a Business Development Intern at Wake Forest Innovations\, fostering the collaborative innovation between industry and the faculty and staff of Wake Forest Baptist Medical Center. After graduate school\, Molly did a brief Medical Writing Fellowship with Impact Pharmaceutical Services. Prior to joining Otsuka\, Molly worked at Reata Pharmaceuticals\, Inc. where she helped to oversee the conduct of clinical trials across a variety of therapeutic areas including nephrology\, neurology\, and pulmonary\, which is where she developed her passion for rare disease. \n\n \n \n\n\n \n \n \n Michael Filsinger\, MPA\, PA-C\n Nephrology Medical Science Liaison\n \n \n \n \n \nOtsuka Pharmaceutical Development & Commercialization\, Inc.*\n \n \n Michael Filsinger\, MPA\, PA-C is a Medical Science Liaison at Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC). Michael earned his Bachelor of Health Care Sciences as well as Master of Physician Assistant at Duquesne University in Pittsburgh\, PA. Following his graduate training\, Michael went on to complete a Pediatric Surgery Residency at Children’s National Medical Center in Washington\, DC Prior to joining Otsuka\, Michael spent the last 15 years working in solid organ transplant in Charlotte\, NC where he developed a passion for improving the care of patients with renal disease and ESKD. \n\n \n \n\n\nEdgar Lerma\, MD is a speaker for Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\nMolly Jansen\, PhD and Michael Filsinger\, MPA\, PA-C are employees of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n \n Registration URL:https://nephu.org/event/iga-nephropathy-pathogenesis-the-role-of-april-and-the-4-hit-process-and-a-patient-case-study/ LOCATION:The Capital Grille – Plano\, 7300 Dallas Parkway\, Texas\, 75024\, United States CATEGORIES:Live Event ATTACH;FMTTYPE=image/jpeg:https://nephu.org/wp-content/uploads/2022/02/IgAN-Cell_resize.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20250708T180000 DTEND;TZID=America/Los_Angeles:20250708T200000 DTSTAMP:20260718T113030 CREATED:20250610T155346Z LAST-MODIFIED:20250618T143457Z UID:10001010-1751997600-1752004800@nephu.org SUMMARY:4 Part IgAN Experience DESCRIPTION:About This Event\n \n \n \n \n \n \n \n \n \n \n IgA Nephropathy: Early Signs & Symptoms\, Disease Burden\, & Management\n An innovative\, four-part educational experience designed to immerse healthcare professionals in the evolving landscape of IgA Nephropathy (IgAN) through interactive technology\, evidence-based literature\, real-world case studies\, and high-impact educational tools.\nProgram Overview\nParticipants will engage in a dynamic dinner event that blends interactive learning with case-based discussions. The program is modular\, allowing requesters to select their preferred literature topic and patient case focus\, while the other elements remain consistent and highly engaging.\n\n \n\n \nB-Cell Biology and the Role of Cytokines in B-Cell Modulation\nThe physiological function of APRIL in B-cell regulation\, and the growing body of evidence supporting APRIL inhibition as a potential therapeutic approach.\n\n \nLiterature Review (Journal Club Style)\n\n RaDaR Study: Long-term outcomes in IgAN and the predictive value of proteinuria and eGFR decline\n\nPresented by Dr. Mohammad Kamgar\n\n \n Apple Vision Pro Immersive Experience\nExperience disease-state education like never before. Using Apple Vision Pro technology\, participants can visually explore:\n\n The 4-hit pathogenic process of IgAN\n The role of APRIL in initiating and sustaining kidney injury in IgAN\n\n \nNephU Resource Station\nHands-on review of pre-approved NephU materials tailored to IgAN\, including:​ \n\n\n Interactive simulators​\n Infographics​\n Educational tools and treatment summaries\n\nPatient Case Study Review\nDive into a real-world case panel discussion on :\n\nPersistent Proteinuria in patients previously considered low risk \n \n\n\n\n\n\n\n \n Location\n \n \n\n\n\n\n\n\n\n\nFeaturing\n\n\n\n \n \n \n Marla Dallal\, PharmD\, RPH\n Nephrology Senior Medical Science Liaison \n \n \n \n \n Otsuka Pharmaceutical Development & Commercialization\, Inc.*\n \n Marla Dallal\, PharmD\, RPH is a Medical Science Liaison at Otsuka Pharmaceutical Development and Commercialization covering Southern California. She earned her Doctor of Pharmacy degree from the University of Southern California\, School of Pharmacy in Los Angeles. While in pharmacy school\, Dr Dallal pursued various clinical internships within the acute care and ambulatory care settings at Cedars-Sinai Medical Center and Kaiser Permanente. Prior to joining Otsuka\, Dr Dallal held various positions within Medical Affairs at Amgen Inc covering the cardiometabolic and nephrology therapeutic areas. She also served as a preceptor at Amgen Inc\, where she instructed pharmacy students on Advanced Pharmacy Practice rotations. She is currently licensed as a pharmacist in the state of California with the National Association Board of Pharmacy. \n\n \n \n\n\n \n \n \n Addis Alemayehu\, PharmD\n Senior Regional Medical Lead\n \n \n \n \n \n \n \n \n \n\n\n \n \n \n Lama Abdelnour\n Assistant Clinical Professor of Medicine\, Medical Director – Living Donor Kidney Transplant Program in Westwood.\n \n \n \n \n Dr. Lama Abdelnour is an Assistant Clinical Professor of Medicine and the Medical Director of the Living Donor Kidney Transplant Program in Westwood. Board-certified in \n \n and Internal Medicine\, she completed her internal medicine training at the University of Nevada School of Medicine in Las Vegas and her nephrology fellowship at the Keck School of Medicine of USC. \nDr. Abdelnour specializes in general nephrology\, with a particular focus on glomerular diseases\, including IgA nephropathy\, Focal Segmental Glomerulosclerosis (FSGS)\, membranous nephropathy\, minimal change disease\, Lupus Nephritis\, and ANCA vasculitis. She is also dedicated to optimizing the health and evaluation of living kidney donors. \nBeyond her clinical practice\, Dr. Abdelnour is a principal investigator on multiple research projects\, contributing to advancements in glomerular diseases and living kidney donation. \n\n \n \n\n\n \n \n \n Mohammad Kamgar\n \n \n \n \n \n \n \n \n \n \n\n\nMarla Dallal\, PharmD\, RPH and Addis Alemayehu\, PharmD are employees of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n \n Registration URL:https://nephu.org/event/4-part-igan-experience/ LOCATION:UCLA Meyer & Renee Luskin Conference Center\, 425 Westwood Plaza\, Los Angeles\, California\, 90095\, United States CATEGORIES:Live Event ATTACH;FMTTYPE=image/jpeg:https://nephu.org/wp-content/uploads/2023/05/webinar-presentation_resize.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20250528T180000 DTEND;TZID=America/Los_Angeles:20250528T200000 DTSTAMP:20260718T113030 CREATED:20250414T223316Z LAST-MODIFIED:20250506T205713Z UID:10001004-1748455200-1748462400@nephu.org SUMMARY:IgA Nephropathy - From Pathogenesis to Current Management DESCRIPTION:About This Event\n \n \n \n \n \n \n \n \n \n \n IgA Nephropathy: Early Signs & Symptoms\, Disease Burden\, & Management\n This presentation is an overview of IgA Nephropathy (IgAN)\, the most common primary glomerular nephropathy worldwide. During this presentation you will learn the clinical presentation\, diagnosis\, prognosis\, and unmet treatment needs of IgAN. You will then take a deep dive into the current understanding of IgAN pathogenesis including the four hit cascade and the key role B-cells and APRIL (A PRoliferation-Inducing Ligand) play in driving disease progression. \n \n\n\n\n\n\n\n \n Location\n \n \n\n\n\n\n\n\n\n\nFeaturing\n\n\n\n \n \n \n Marla Dallal\, PharmD\, RPH\n Nephrology Senior Medical Science Liaison \n \n \n \n \n Otsuka Pharmaceutical Development & Commercialization\, Inc.*\n \n Marla Dallal\, PharmD\, RPH is a Medical Science Liaison at Otsuka Pharmaceutical Development and Commercialization covering Southern California. She earned her Doctor of Pharmacy degree from the University of Southern California\, School of Pharmacy in Los Angeles. While in pharmacy school\, Dr Dallal pursued various clinical internships within the acute care and ambulatory care settings at Cedars-Sinai Medical Center and Kaiser Permanente. Prior to joining Otsuka\, Dr Dallal held various positions within Medical Affairs at Amgen Inc covering the cardiometabolic and nephrology therapeutic areas. She also served as a preceptor at Amgen Inc\, where she instructed pharmacy students on Advanced Pharmacy Practice rotations. She is currently licensed as a pharmacist in the state of California with the National Association Board of Pharmacy. \n\n \n \n\n\nMarla Dallal\, PharmD\, RPH is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n \n Registration URL:https://nephu.org/event/iga-nephropathy-from-pathogenesis-to-current-management-39/ LOCATION:Mastro’s Steakhouse – CA\, 2087 E Thousand Oaks Blvd\, Thousand Oaks\, California\, 91362\, United States CATEGORIES:Live Event ATTACH;FMTTYPE=image/jpeg:https://nephu.org/wp-content/uploads/2022/02/IgAN-Cell_resize.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20250521T180000 DTEND;TZID=America/Los_Angeles:20250521T200000 DTSTAMP:20260718T113030 CREATED:20250414T222950Z LAST-MODIFIED:20250415T165936Z UID:10001003-1747850400-1747857600@nephu.org SUMMARY:IgA Nephropathy - From Pathogenesis to Current Management DESCRIPTION:About This Event\n \n \n \n \n \n \n \n \n \n \n IgA Nephropathy: Early Signs & Symptoms\, Disease Burden\, & Management\n This presentation is an overview of IgA Nephropathy (IgAN)\, the most common primary glomerular nephropathy worldwide. During this presentation you will learn the clinical presentation\, diagnosis\, prognosis\, and unmet treatment needs of IgAN. You will then take a deep dive into the current understanding of IgAN pathogenesis including the four hit cascade and the key role B-cells and APRIL (A PRoliferation-Inducing Ligand) play in driving disease progression. \n \n\n\n\n\n\n\n \n Location\n \n \n\n\n\n\n\n\n\n\nFeaturing\n\n\n\n \n \n \n Marla Dallal\, PharmD\, RPH\n Nephrology Senior Medical Science Liaison \n \n \n \n \n Otsuka Pharmaceutical Development & Commercialization\, Inc.*\n \n Marla Dallal\, PharmD\, RPH is a Medical Science Liaison at Otsuka Pharmaceutical Development and Commercialization covering Southern California. She earned her Doctor of Pharmacy degree from the University of Southern California\, School of Pharmacy in Los Angeles. While in pharmacy school\, Dr Dallal pursued various clinical internships within the acute care and ambulatory care settings at Cedars-Sinai Medical Center and Kaiser Permanente. Prior to joining Otsuka\, Dr Dallal held various positions within Medical Affairs at Amgen Inc covering the cardiometabolic and nephrology therapeutic areas. She also served as a preceptor at Amgen Inc\, where she instructed pharmacy students on Advanced Pharmacy Practice rotations. She is currently licensed as a pharmacist in the state of California with the National Association Board of Pharmacy. \n\n \n \n\n\nMarla Dallal\, PharmD\, RPH is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n \n Registration URL:https://nephu.org/event/iga-nephropathy-from-pathogenesis-to-current-management-38/ LOCATION:Fleming’s Prime Steakhouse & Wine Bar Newport Beach\, 445 Newport Center Dr\, Newport Beach\, California\, 92660\, United States CATEGORIES:Live Event ATTACH;FMTTYPE=image/jpeg:https://nephu.org/wp-content/uploads/2022/06/IgAN-title-image_resize.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/North_Dakota/New_Salem:20250508T183000 DTEND;TZID=America/North_Dakota/New_Salem:20250508T210000 DTSTAMP:20260718T113030 CREATED:20250319T154640Z LAST-MODIFIED:20250319T163226Z UID:10000994-1746729000-1746738000@nephu.org SUMMARY:IgA Nephropathy - From Pathogenesis to Current Management DESCRIPTION:About This Event\n \n \n \n \n \n \n \n \n \n \n IgA Nephropathy: Early Signs & Symptoms\, Disease Burden\, & Management\n This presentation is an overview of IgA Nephropathy (IgAN)\, the most common primary glomerular nephropathy worldwide. During this presentation you will learn the clinical presentation\, diagnosis\, prognosis\, and unmet treatment needs of IgAN. You will then take a deep dive into the current understanding of IgAN pathogenesis including the four hit cascade and the key role B-cells and APRIL (A PRoliferation-Inducing Ligand) play in driving disease progression. \n \n\n\n\n\n\n\n \n Location\n \n \n\n\n\n\n\n\n\n\nFeaturing\n\n\n\n \n \n \n Bolanle Soyombo\, PharmD\, BCACP\n Medical Science Liaison\, Nephrology\n \n \n \n \n Dr. Bolanle Soyombo is a Medical Science Liaison at Otsuka\, board-certified in ambulatory care. She holds a PharmD from the University of Houston and has managed chronic diseases at Ochsner Health and Devoted Health.\n \n Bolanle Soyombo is a medical science liaison at Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC). Dr. Soyombo received her doctorate in pharmacy from the University of Houston College of Pharmacy in 2018 and went on to complete an ambulatory care focused PGY1 residency at Xavier University of Louisiana. Prior to joining Otsuka\, Dr. Soyombo worked for Ochsner Health in the Digital Medicine Department where she independent managed chronic diseases for patients in the greater New Orleans Area. She went on to work for Devoted Health where she broadened her reach to patient populations across 7 states in the US. Dr. Soyombo has a passion for disease state management and education. She is a board-certified ambulatory care pharmacist. \n\n \n \n\n\nBolanle Soyombo\, PharmD\, BCACP is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n \n Registration URL:https://nephu.org/event/iga-nephropathy-from-pathogenesis-to-current-management-30/ LOCATION:Grotto Ristorante\, 4715 Westheimer Rd\, Houston\, TX\, 77027\, United States CATEGORIES:Live Event ATTACH;FMTTYPE=image/jpeg:https://nephu.org/wp-content/uploads/2022/06/IgAN-title-image_resize.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20250506T183000 DTEND;TZID=America/New_York:20250506T210000 DTSTAMP:20260718T113030 CREATED:20250423T172610Z LAST-MODIFIED:20250423T182458Z UID:10001006-1746556200-1746565200@nephu.org SUMMARY:4-Part IgAN Experience: An Immersive\, Interactive Dinner Series Brought to You by NephU DESCRIPTION:About This Event\n \n \n \n \n \n \n \n \n \n \n IgA Nephropathy: Early Signs & Symptoms\, Disease Burden\, & Management\n Step into an educational journey designed to deepen your understanding of IgA Nephropathy (IgAN) through an engaging\, multi-format learning experience—powered by cutting-edge tools and real-world insights.\n\nHere’s what to expect across the evening’s four parts: \n\nApple Vision Pro Interactive Module \n\nExperience a groundbreaking new way to learn about IgAN. Through Apple Vision Pro\, dive into the pathogenic cascade that leads to kidney injury and explore the role of APRIL\, a key initiating and sustaining factor in IgAN. This immersive mixed-reality module puts disease education right before your eyes—literally. \n\nJournal Club: RaDaR Literature Review \n\nReview long-term outcomes from the UK’s National Registry of Rare Kidney Diseases (RaDaR) and explore how short-term changes in proteinuria and eGFR slope relate to lifetime kidney failure risk. Gain insights into evolving markers for disease progression and their impact on patient care. \n\nPatient Case Deep Dive: Persistent Proteinuria \n\nIgAN previously has been considered a benign disease\, particularly for patients below the target proteinuria level of <1 g/d. However\, studies suggest that the risk of progression to ESKD cannot be ignored\, even for patients traditionally considered low risk. Join us for a patient case discussion regarding persistent proteinuria! \n\nResource Showcase \n\nBrowse a curated set of NephU-approved educational tools\, infographics\, and simulators to support HCP education beyond the dinner. Connect with MSLs to get the most from these high-value resources. \n \n\n\n\n\n\n\n \n Location\n \n \n\n\n\n\n\n\n\n\nFeaturing\n\n\n\n \n \n \n Max Hyams\, PharmD\, RPh\n Nephrology Medical Science Liaison\n \n \n \n \n \nOtsuka Pharmaceutical Development & Commercialization\, Inc.*\n \n \n Max Hyams\, PharmD\, RPh\, is a Nephrology Medical Science Liaison at Otsuka Pharmaceutical Development & Commercialization (OPDC) covering New Jersey. He earned his Doctorate of Pharmacy from Albany College of Pharmacy and Health Sciences in Albany\, New York. Prior to joining Otsuka\, he was a Global Pharmacovigilance Case Processor in Specialty Medicine at Bayer\, working closely with colleagues in Brazil and Germany. Prior to that\, he was a Pharmacy Manager for CVS\, working in the highest volume\, 24-hour stores in Northern New Jersey\, and has experience working for an independent pharmacy specializing in fertility medications. He is currently licensed as a pharmacist in New Jersey and resides in Hoboken\, New Jersey. \n\n \n \n\n\n \n \n \n Andrea Mohindra\, PharmD\n Nephrology Medical Science Liaison\n \n \n \n \n Otsuka Pharmaceutical Development & Commercialization\, Inc.* \n \n Andrea Mohindra\, PharmD\, is a Nephrology Medical Science Liaison covering New York City & Long Island. She earned her PharmD at the University of Rhode Island in South Kingstown\, RI. Prior to joining Otsuka in 2021\, Dr Mohindra held various leadership roles in retail pharmacy for 15 years in the NJ and NYC regions. Most recently\, she held the role of Doctor Partnership Manager for a retail pharmacy startup company and worked closely with Psychiatrists and Migraine Specialists. She is currently licensed in New Jersey and New York state. \n\n \n \n\n\n \n \n \n Kartik Kalra\, MD\n Clinical Associate in Nephrology\, Associate Program Director of Nephrology Fellowship training program – Geisinger Medical Center; Assistant Professor of Medicine – Geisinger Commonwealth School of Medicine\n \n \n \n \n Kartik Kalra\, MD\, is a Clinical Associate in Nephrology and serves as the Associate Program Director of the Nephrology Fellowship training program at Geisinger Medical \n \n in Danville\, PA. Additionally\, he is an Assistant Professor of Medicine at Geisinger Commonwealth School of Medicine. Dr. Kalra completed his internal medicine residency at St. Peter’s University Hospital\, Rutgers\, NJ\, and then pursued a nephrology fellowship at the University of Pittsburgh Medical Center. He further specialized in glomerular disease through GLOMCON fellowship\, where he currently acts as a faculty mentor. His primary areas of interest include glomerular disease\, peritoneal dialysis\, ICU nephrology\, and electrolyte abnormalities. He has published peer-reviewed articles and presented numerous posters at national and international conferences. Dr. Kalra has been honored with the David R. Gutknecht Award for excellence in clinical teaching at Geisinger and is featured on the Internal Medicine Faculty Honor Roll. He is a senior member of the Geisinger Academy of Educators and a Fellow of both the American Society of Nephrology and the National Kidney Foundation. \n\n \n \n\n\nMax Hyams\, PharmD\, RPh and Andrea Mohindra\, PharmD are employees of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\nKartik Kalra\, MD is a Community Advisor for Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n \n Registration URL:https://nephu.org/event/4-part-igan-experience-an-immersive-interactive-dinner-series-brought-to-you-by-nephu/ LOCATION:Ruth’s Chris Steak House – Maywood\, 83 W Spring Valley Ave L-6\, Maywood\, New Jersey\, 07607\, United States CATEGORIES:Live Event ATTACH;FMTTYPE=image/jpeg:https://nephu.org/wp-content/uploads/2022/06/IgAN-title-image_resize.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20250424T183000 DTEND;TZID=America/Los_Angeles:20250424T210000 DTSTAMP:20260718T113030 CREATED:20250402T210621Z LAST-MODIFIED:20250403T195454Z UID:10000997-1745519400-1745528400@nephu.org SUMMARY:IgA Nephropathy - From Pathogenesis to Current Management DESCRIPTION:About This Event\n \n \n \n \n \n \n \n \n \n \n IgA Nephropathy: Early Signs & Symptoms\, Disease Burden\, & Management\n This presentation is an overview of IgA Nephropathy (IgAN)\, the most common primary glomerular nephropathy worldwide. During this presentation you will learn the clinical presentation\, diagnosis\, prognosis\, and unmet treatment needs of IgAN. You will then take a deep dive into the current understanding of IgAN pathogenesis including the four hit cascade and the key role B-cells and APRIL (A PRoliferation-Inducing Ligand) play in driving disease progression. \n \n\n\n\n\n\n\n \n Location\n \n \n\n\n\n\n\n\n\n\nFeaturing\n\n\n\n \n \n \n Sushma Shiravanthe\, PharmD\, BCPS\n Nephrology Medical Science Liaison\n \n \n \n \n Otsuka Pharmaceutical Development & Commercialization\, Inc.* \n \n Sushma Shiravanthe\, PharmD\, BCPS\, is a Medical Science Liaison at Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) covering Northern California. Dr. Shiravanthe earned her BS in Brain\, Behavior\, and Cognitive Science and Doctorate of Pharmacy degrees from the University of Michigan in Ann Arbor\, MI. She completed residency training at Ascension St. Vincent Anderson in Anderson\, IN during which time she also earned a teaching certificate from Purdue University College of Pharmacy. Dr. Shiravanthe is Board Certified in Pharmacotherapy (BCPS) and is a licensed pharmacist in Indiana and California. Prior to joining Otsuka\, Dr. Shiravanthe worked as a clinical pharmacist at Ascension St. Vincent Anderson for 2.5 years\, and as a clinical pharmacy specialist at the Department of Veterans Affairs Palo Alto Healthcare System for 3 years. During this time\, she also served as a preceptor for the pharmacy residency program clinical teaching skills\, grand rounds\, and clinical research rotations. Her clinical practice experience includes internal medicine\, cardio-renal diseases\, infectious diseases\, and geriatrics. \n\n \n \n\n\nSushma Shiravanthe\, PharmD\, BCPS is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n \n Registration URL:https://nephu.org/event/iga-nephropathy-from-pathogenesis-to-current-management-33/ LOCATION:Paul Martin’s American Grill\, 101 Hillsdale Shopping Ctr\, San Mateo\, California\, 94403\, United States CATEGORIES:Live Event ATTACH;FMTTYPE=image/jpeg:https://nephu.org/wp-content/uploads/2023/01/medical-reporting_resize.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20250423T183000 DTEND;TZID=America/Los_Angeles:20250423T200000 DTSTAMP:20260718T113030 CREATED:20250411T175421Z LAST-MODIFIED:20250414T163311Z UID:10001002-1745433000-1745438400@nephu.org SUMMARY:IgA Nephropathy - From Pathogenesis to Current Management DESCRIPTION:About This Event\n \n \n \n \n \n \n \n \n \n \n IgA Nephropathy: Early Signs & Symptoms\, Disease Burden\, & Management\n This presentation is an overview of IgA Nephropathy (IgAN)\, the most common primary glomerular nephropathy worldwide. During this presentation you will learn the clinical presentation\, diagnosis\, prognosis\, and unmet treatment needs of IgAN. You will then take a deep dive into the current understanding of IgAN pathogenesis including the four hit cascade and the key role B-cells and APRIL (A PRoliferation-Inducing Ligand) play in driving disease progression.\n \n \n\n\n\n\n\n\n \n Location\n \n \n\n\n\n\n\n\n\n\nFeaturing\n\n\n\n \n \n \n Marla Dallal\, PharmD\, RPH\n Nephrology Senior Medical Science Liaison \n \n \n \n \n Otsuka Pharmaceutical Development & Commercialization\, Inc.*\n \n Marla Dallal\, PharmD\, RPH is a Medical Science Liaison at Otsuka Pharmaceutical Development and Commercialization covering Southern California. She earned her Doctor of Pharmacy degree from the University of Southern California\, School of Pharmacy in Los Angeles. While in pharmacy school\, Dr Dallal pursued various clinical internships within the acute care and ambulatory care settings at Cedars-Sinai Medical Center and Kaiser Permanente. Prior to joining Otsuka\, Dr Dallal held various positions within Medical Affairs at Amgen Inc covering the cardiometabolic and nephrology therapeutic areas. She also served as a preceptor at Amgen Inc\, where she instructed pharmacy students on Advanced Pharmacy Practice rotations. She is currently licensed as a pharmacist in the state of California with the National Association Board of Pharmacy. \n\n \n \n\n\nMarla Dallal\, PharmD\, RPH is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n \n Registration URL:https://nephu.org/event/iga-nephropathy-from-pathogenesis-to-current-management-37/ LOCATION:Greensleeves Steakhouse\, 220 Orange St\, Redlands\, CA\, 92374\, United States CATEGORIES:Live Event ATTACH;FMTTYPE=image/jpeg:https://nephu.org/wp-content/uploads/2022/12/IgAN-Overview-podcast_resize.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Denver:20250416T180000 DTEND;TZID=America/Denver:20250416T200000 DTSTAMP:20260718T113030 CREATED:20250307T225305Z LAST-MODIFIED:20250312T193604Z UID:10000993-1744826400-1744833600@nephu.org SUMMARY:IgA Nephropathy - From Pathogenesis to Current Management DESCRIPTION:About This Event\n \n \n \n \n \n \n \n \n \n \n IgA Nephropathy: Early Signs & Symptoms\, Disease Burden\, & Management\n This presentation is an overview of IgA Nephropathy (IgAN)\, the most common primary glomerular nephropathy worldwide. During this presentation you will learn the clinical presentation\, diagnosis\, prognosis\, and unmet treatment needs of IgAN. You will then take a deep dive into the current understanding of IgAN pathogenesis including the four hit cascade and the key role B-cells and APRIL (A PRoliferation-Inducing Ligand) play in driving disease progression. \n \n\n\n\n\n\n\n \n Location\n \n \n\n\n\n\n\n\n\n\nFeaturing\n\n\n\n \n \n \n Sachin Hajarnis\, PhD\n Nephrology Medical Science Director\n \n \n \n \n Otsuka Pharmaceutical Development & Commercialization\, Inc.* \n \n Sachin Hajarnis\, PhD is a Senior Medical Science Liaison at Otsuka Pharmaceuticals. Dr Hajarnis has a Bachelors and Masters in Life Sciences from University of Mumbai\, India. He obtained a PhD in Biochemistry and Molecular Biology from Colorado State University. Dr Hajarnis joined the University of Texas Southwestern Medical school in Dallas\, as a post-doctoral fellow in the department of Nephrology where he performed basic research on various aspects of Polycystic Kidney Disease (PKD). He continued his studies on the role of micro-RNAs in PKD as a Research Scientist for several years before joining his current position at Otsuka. \n\n \n \n\n\nSachin Hajarnis\, PhD is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n \n Registration URL:https://nephu.org/event/iga-nephropathy-from-pathogenesis-to-current-management-29/ LOCATION:Vintage 423\, 8000 Paseo Del Norte Drive\,\, Albuquerque\, NM\, 87122\, United States CATEGORIES:Live Event ATTACH;FMTTYPE=image/jpeg:https://nephu.org/wp-content/uploads/2022/12/IgAN-Overview-podcast_resize.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20250313T183000 DTEND;TZID=America/Los_Angeles:20250313T210000 DTSTAMP:20260718T113030 CREATED:20250214T004049Z LAST-MODIFIED:20250221T152419Z UID:10000984-1741890600-1741899600@nephu.org SUMMARY:IgA Nephropathy - From Pathogenesis to Current Management DESCRIPTION:About This Event\n \n \n \n \n \n \n \n \n \n \n IgA Nephropathy: Early Signs & Symptoms\, Disease Burden\, & Management\n This presentation is an overview of IgA Nephropathy (IgAN)\, the most common primary glomerular nephropathy worldwide. During this presentation you will learn the clinical presentation\, diagnosis\, prognosis\, and unmet treatment needs of IgAN. You will then take a deep dive into the current understanding of IgAN pathogenesis including the four hit cascade and the key role B-cells and APRIL (A PRoliferation-Inducing Ligand) play in driving disease progression. \n \n\n\n\n\n\n\n \n Location\n \n \n\n\n\n\n\n\n\n\nFeaturing\n\n\n\n \n \n \n Sushma Shiravanthe\, PharmD\, BCPS\n Nephrology Medical Science Liaison\n \n \n \n \n Otsuka Pharmaceutical Development & Commercialization\, Inc.* \n \n Sushma Shiravanthe\, PharmD\, BCPS\, is a Medical Science Liaison at Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) covering Northern California. Dr. Shiravanthe earned her BS in Brain\, Behavior\, and Cognitive Science and Doctorate of Pharmacy degrees from the University of Michigan in Ann Arbor\, MI. She completed residency training at Ascension St. Vincent Anderson in Anderson\, IN during which time she also earned a teaching certificate from Purdue University College of Pharmacy. Dr. Shiravanthe is Board Certified in Pharmacotherapy (BCPS) and is a licensed pharmacist in Indiana and California. Prior to joining Otsuka\, Dr. Shiravanthe worked as a clinical pharmacist at Ascension St. Vincent Anderson for 2.5 years\, and as a clinical pharmacy specialist at the Department of Veterans Affairs Palo Alto Healthcare System for 3 years. During this time\, she also served as a preceptor for the pharmacy residency program clinical teaching skills\, grand rounds\, and clinical research rotations. Her clinical practice experience includes internal medicine\, cardio-renal diseases\, infectious diseases\, and geriatrics. \n\n \n \n\n\nSushma Shiravanthe\, PharmD\, BCPS is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n \n Registration URL:https://nephu.org/event/iga-nephropathy-from-pathogenesis-to-current-management-22/ LOCATION:Maggiano’s Little Italy\, 3055 Olin Ave Suite 1000\, San Jose\, California\, 95128\, United States CATEGORIES:Live Event ATTACH;FMTTYPE=image/jpeg:https://nephu.org/wp-content/uploads/2022/06/IgAN-title-image_resize.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20250312T180000 DTEND;TZID=America/Los_Angeles:20250312T210000 DTSTAMP:20260718T113030 CREATED:20250211T220358Z LAST-MODIFIED:20250214T143320Z UID:10000980-1741802400-1741813200@nephu.org SUMMARY:IgA Nephropathy - From Pathogenesis to Current Management DESCRIPTION:About This Event\n \n \n \n \n \n \n \n \n \n \n IgA Nephropathy: Early Signs & Symptoms\, Disease Burden\, & Management\n This presentation is an overview of IgA Nephropathy (IgAN)\, the most common primary glomerular nephropathy worldwide. During this presentation you will learn the clinical presentation\, diagnosis\, prognosis\, and unmet treatment needs of IgAN. You will then take a deep dive into the current understanding of IgAN pathogenesis including the four hit cascade and the key role B-cells and APRIL (A PRoliferation-Inducing Ligand) play in driving disease progression. \n \n\n\n\n\n\n\n \n Location\n \n \n\n\n\n\n\n\n\n\nFeaturing\n\n\n\n \n \n \n Sara Nam\, PharmD\, BCCCP\n Nephrology Medical Science Liaison\n \n \n \n \n Otsuka Pharmaceutical Development & Commercialization\, Inc.* \n \n Sara Nam\, PharmD\, BCCCP is a Medical Science Liaison at Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) covering the Pacific Northwest Territory. Dr. Nam earned her Doctorate in Pharmacy from the University of Oklahoma and completed her postgraduate general pharmacy residency at Oklahoma State University Medical Center and her postgraduate critical care pharmacy residency at Memorial Hermann-Texas Medical Center.  Prior to joining Otsuka\, Dr. Nam practiced as an Emergency Medicine Pharmacy Specialist at the Methodist Health System in Dallas\, TX and as a Portfolio Executive for Pharmacy Sourcing at Vizient\, Inc.  Dr. Nam holds a board certification in critical care pharmacotherapy. \n\n \n \n\n\nSara Nam\, PharmD\, BCCCP is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n \n Registration URL:https://nephu.org/event/iga-nephropathy-from-pathogenesis-to-current-management-21/ LOCATION:Ocean Prime Family Restaurant\, 107 SW Interstate Ave\, Chehalis\, WA\, 98532\, United States CATEGORIES:Live Event ATTACH;FMTTYPE=image/jpeg:https://nephu.org/wp-content/uploads/2022/02/IgAN-Cell_resize.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/North_Dakota/New_Salem:20250220T183000 DTEND;TZID=America/North_Dakota/New_Salem:20250220T210000 DTSTAMP:20260718T113030 CREATED:20250212T145325Z LAST-MODIFIED:20250212T152831Z UID:10000982-1740076200-1740085200@nephu.org SUMMARY:IgA Nephropathy - From Pathogenesis to Current Management DESCRIPTION:About This Event\n \n \n \n \n \n \n \n \n \n \n IgA Nephropathy: Early Signs & Symptoms\, Disease Burden\, & Management\n This presentation is an overview of IgA Nephropathy (IgAN)\, the most common primary glomerular nephropathy worldwide. During this presentation you will learn the clinical presentation\, diagnosis\, prognosis\, and unmet treatment needs of IgAN. You will then take a deep dive into the current understanding of IgAN pathogenesis including the four hit cascade and the key role B-cells and APRIL (A PRoliferation-Inducing Ligand) play in driving disease progression. \n \n\n\n\n\n\n\n \n Location\n \n \n\n\n\n\n\n\n\n\nFeaturing\n\n\n\n \n \n \n Bolanle Soyombo\, PharmD\, BCACP\n Medical Science Liaison\, Nephrology\n \n \n \n \n Dr. Bolanle Soyombo is a Medical Science Liaison at Otsuka\, board-certified in ambulatory care. She holds a PharmD from the University of Houston and has managed chronic diseases at Ochsner Health and Devoted Health.\n \n Bolanle Soyombo is a medical science liaison at Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC). Dr. Soyombo received her doctorate in pharmacy from the University of Houston College of Pharmacy in 2018 and went on to complete an ambulatory care focused PGY1 residency at Xavier University of Louisiana. Prior to joining Otsuka\, Dr. Soyombo worked for Ochsner Health in the Digital Medicine Department where she independent managed chronic diseases for patients in the greater New Orleans Area. She went on to work for Devoted Health where she broadened her reach to patient populations across 7 states in the US. Dr. Soyombo has a passion for disease state management and education. She is a board-certified ambulatory care pharmacist. \n\n \n \n\n\nBolanle Soyombo\, PharmD\, BCACP is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n \n Registration URL:https://nephu.org/event/iga-nephropathy-from-pathogenesis-to-current-management-19/ LOCATION:Pappadeaux Seafood Kitchen\, 6319 N Interstate Hwy 35\, Austin\, Texas\, 78752\, United States CATEGORIES:Live Event ATTACH;FMTTYPE=image/jpeg:https://nephu.org/wp-content/uploads/2022/06/IgAN-title-image_resize.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/North_Dakota/New_Salem:20241219T180000 DTEND;TZID=America/North_Dakota/New_Salem:20241219T203000 DTSTAMP:20260718T113030 CREATED:20241120T205815Z LAST-MODIFIED:20241122T175748Z UID:10000972-1734631200-1734640200@nephu.org SUMMARY:IgA Nephropathy - From Pathogenesis to Current Management DESCRIPTION:About This Event\n \n \n \n \n \n \n \n \n \n \n IgA Nephropathy: Early Signs & Symptoms\, Disease Burden\, & Management\n This presentation is an overview of IgA Nephropathy (IgAN)\, the most common primary glomerular nephropathy worldwide. During this presentation you will learn the clinical presentation\, diagnosis\, prognosis\, and unmet treatment needs of IgAN. You will then take a deep dive into the current understanding of IgAN pathogenesis including the four hit cascade and the key role B-cells and APRIL (A PRoliferation-Inducing Ligand) play in driving disease progression. \n \n\n\n\n\n\n\n \n Location\n \n \n\n\n\n\n\n\n\n\nFeaturing\n\n\n\n \n \n \n Bolanle Soyombo\, PharmD\, BCACP\n Medical Science Liaison\, Nephrology\n \n \n \n \n Dr. Bolanle Soyombo is a Medical Science Liaison at Otsuka\, board-certified in ambulatory care. She holds a PharmD from the University of Houston and has managed chronic diseases at Ochsner Health and Devoted Health.\n \n Bolanle Soyombo is a medical science liaison at Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC). Dr. Soyombo received her doctorate in pharmacy from the University of Houston College of Pharmacy in 2018 and went on to complete an ambulatory care focused PGY1 residency at Xavier University of Louisiana. Prior to joining Otsuka\, Dr. Soyombo worked for Ochsner Health in the Digital Medicine Department where she independent managed chronic diseases for patients in the greater New Orleans Area. She went on to work for Devoted Health where she broadened her reach to patient populations across 7 states in the US. Dr. Soyombo has a passion for disease state management and education. She is a board-certified ambulatory care pharmacist. \n\n \n \n\n\nBolanle Soyombo\, PharmD\, BCACP is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n \n Registration URL:https://nephu.org/event/iga-nephropathy-from-pathogenesis-to-current-management-16/ LOCATION:Perry’s Steakhouse & Grille – River Oaks\, 1997 West Gray St\, Houston\, Texas\, 77019\, United States CATEGORIES:Live Event ATTACH;FMTTYPE=image/jpeg:https://nephu.org/wp-content/uploads/2023/06/Imaging-report-TKV_resize.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20241114T183000 DTEND;TZID=America/Los_Angeles:20241114T210000 DTSTAMP:20260718T113030 CREATED:20240911T204609Z LAST-MODIFIED:20240917T134253Z UID:10000962-1731609000-1731618000@nephu.org SUMMARY:IgA Nephropathy - From Pathogenesis to Current Management DESCRIPTION:About This Event\n \n \n \n \n \n \n \n \n \n \n IgA Nephropathy: Early Signs & Symptoms\, Disease Burden\, & Management\n This presentation is an overview of IgA Nephropathy (IgAN)\, the most common primary glomerular nephropathy worldwide. During this presentation you will learn the clinical presentation\, diagnosis\, prognosis\, and unmet treatment needs of IgAN. You will then take a deep dive into the current understanding of IgAN pathogenesis including the four hit cascade and the key role B-cells and APRIL (A PRoliferation-Inducing Ligand) play in driving disease progression. \n \n\n\n\n\n\n\n \n Location\n \n \n\n\n\n\n\n\n\n\nFeaturing\n\n\n\n \n \n \n Sushma Shiravanthe\, PharmD\, BCPS\n Nephrology Medical Science Liaison\n \n \n \n \n Otsuka Pharmaceutical Development & Commercialization\, Inc.* \n \n Sushma Shiravanthe\, PharmD\, BCPS\, is a Medical Science Liaison at Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) covering Northern California. Dr. Shiravanthe earned her BS in Brain\, Behavior\, and Cognitive Science and Doctorate of Pharmacy degrees from the University of Michigan in Ann Arbor\, MI. She completed residency training at Ascension St. Vincent Anderson in Anderson\, IN during which time she also earned a teaching certificate from Purdue University College of Pharmacy. Dr. Shiravanthe is Board Certified in Pharmacotherapy (BCPS) and is a licensed pharmacist in Indiana and California. Prior to joining Otsuka\, Dr. Shiravanthe worked as a clinical pharmacist at Ascension St. Vincent Anderson for 2.5 years\, and as a clinical pharmacy specialist at the Department of Veterans Affairs Palo Alto Healthcare System for 3 years. During this time\, she also served as a preceptor for the pharmacy residency program clinical teaching skills\, grand rounds\, and clinical research rotations. Her clinical practice experience includes internal medicine\, cardio-renal diseases\, infectious diseases\, and geriatrics. \n\n \n \n\n\nSushma Shiravanthe\, PharmD\, BCPS is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n \n Registration URL:https://nephu.org/event/iga-nephropathy-from-pathogenesis-to-current-management-12/ LOCATION:Fleming’s Prime Steakhouse & Wine Bar\, 180 El Camino Real G-2\, Palo Alto\, California\, 94304\, United States CATEGORIES:Live Event ATTACH;FMTTYPE=image/jpeg:https://nephu.org/wp-content/uploads/2022/02/IgAN-Cell_resize.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20241009T180000 DTEND;TZID=America/Los_Angeles:20241009T200000 DTSTAMP:20260718T113030 CREATED:20241002T061325Z LAST-MODIFIED:20241003T141735Z UID:10000964-1728496800-1728504000@nephu.org SUMMARY:IgA Nephropathy - From Pathogenesis to Current Management DESCRIPTION:About This Event\n \n \n \n \n \n \n \n \n \n \n IgA Nephropathy: Early Signs & Symptoms\, Disease Burden\, & Management\n This presentation is an overview of IgA Nephropathy (IgAN)\, the most common primary glomerular nephropathy worldwide. During this presentation you will learn the clinical presentation\, diagnosis\, prognosis\, and unmet treatment needs of IgAN. You will then take a deep dive into the current understanding of IgAN pathogenesis including the four hit cascade and the key role B-cells and APRIL (A PRoliferation-Inducing Ligand) play in driving disease progression. \n \n\n\n\n\n\n\n \n Location\n \n \n\n\n\n\n\n\n\n\nFeaturing\n\n\n\n \n \n \n Rim Hadgu\, PharmD\, BCPS\n Nephrology Medical Science Liaison\n \n \n \n \n Otsuka Pharmaceutical Development & Commercialization\, Inc.* \n \n Dr Rim Hadgu\, PharmD\, BCPS is a Nephrology Medical Science Liaison at Otsuka Pharmaceutical Development and Commercialization. She obtained her Doctor of Pharmacy degree from St. Louis College of Pharmacy. She completed an American Society of Health-System Pharmacists (ASHP)-Accredited PGY1 Pharmacy Residency at Xavier University of Louisiana College of Pharmacy and University Medical Center New Orleans. She also completed an ASHP-Accredited PGY2 Nephrology Pharmacy Residency at Albany College of Pharmacy and Health Sciences. Prior to joining Otsuka in October 2021\, she was an Assistant Professor of Pharmacy Practice at Midwestern University College of Pharmacy\, Glendale Campus where she delivered lectures\, precepted Advanced Pharmacy Practice Experience students as well as PGY1 and PGY2 pharmacy residents. She also practiced as a nephrology clinical pharmacist for two years. Dr Hadgu is a Board Certified Pharmacotherapy Specialist by the Board of Pharmacy Specialties. \n\n \n \n\n\n \n \n \n Dr. Samuel Kantor\, MD\n Nephrologists Partner\n \n \n \n \n Nephrologist Partner \n \n Samuel Kantor\, MD \nNephrologist Partner \nNevada Kidney Disease and Hypertension Centers* \nDr Kantor received his postgraduate training at Medical College of Pennsylvania and Hahnemann University College of Medicine in Philadelphia\, PA. Dr Kantor did his fellowship training at Drexel University College of Medicine in Philadelphia\, PA and was Chief Nephrology Fellow. He is a partner at Nevada Kidney Disease and Hypertension Centers in Las Vegas\, NV and is a principal investigator and sub-investigator in multiple phase 2 and 3 clinical studies undertaken by the practice. Dr Kantor has been board-certified in Nephrology since 2003. He was awarded ‘Top Doctor’ Status by Las Vegas INC. Magazine in their healthcare issue in 2015\, 2016\, and 2023. He was also awarded ‘Top Doctor’ status by Desert Companion Magazine in 2021 and 2022. \n\n \n \n\n\nRim Hadgu\, PharmD\, BCPS is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\nSamuel Kantor\, MD is a speaker on behalf of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n \n Registration URL:https://nephu.org/event/iga-nephropathy-from-pathogenesis-to-current-management-13/ LOCATION:Americana\, 2620 Regatta Dr Ste 118\, Las Vegas\, NV\, 89128\, United States CATEGORIES:Live Event ATTACH;FMTTYPE=image/jpeg:https://nephu.org/wp-content/uploads/2022/06/IgAN-title-image_resize.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20240226T183000 DTEND;TZID=America/New_York:20240226T203000 DTSTAMP:20260718T113030 CREATED:20240117T203447Z LAST-MODIFIED:20240301T180109Z UID:10000895-1708972200-1708979400@nephu.org SUMMARY:Understanding Polycystic Kidney Disease: An Overview of PKD DESCRIPTION:About This Event\n \n \n \n \n \n \n \n \n \n \n IgA Nephropathy: Early Signs & Symptoms\, Disease Burden\, & Management\n This presentation for patients will discuss how Polycystic Kidney Disease (PKD) develops\, how the disease changes over time\, and how it affects patients both physically and mentally.\n \n \n\n\n\n\n\n\n \n Location\n \n \n\n\n\n\n\n\n\n\nFeaturing\n\n\n\n \n \n \n Andrea Mohindra\, PharmD\n Nephrology Medical Science Liaison\n \n \n \n \n Otsuka Pharmaceutical Development & Commercialization\, Inc.* \n \n Andrea Mohindra\, PharmD\, is a Nephrology Medical Science Liaison covering New York City & Long Island. She earned her PharmD at the University of Rhode Island in South Kingstown\, RI. Prior to joining Otsuka in 2021\, Dr Mohindra held various leadership roles in retail pharmacy for 15 years in the NJ and NYC regions. Most recently\, she held the role of Doctor Partnership Manager for a retail pharmacy startup company and worked closely with Psychiatrists and Migraine Specialists. She is currently licensed in New Jersey and New York state. \n\n \n \n\n\n \n \n \n Shayan Shirazian\, MD\n Associate Professor of Medicine\, Nephrology \n \n \n \n \n \nColumbia University Medical Center*\n \n \n Dr Shirazian received his undergraduate and medical degrees from Brown University and did his internal medicine residency and nephrology fellowship at the Columbia University Irving Medical Center. He spent 7 years at NYU-Winthrop Hospital where he was the fellowship program director and the director of nephrology clinical trials before being recruited back to Columbia. He is currently an associate professor of medicine in nephrology and a director of in-center and home dialysis at Columbia. \nHis research aims to test\, and implement\, interventions to improve quality of life and self-care in patients with chronic kidney disease (CKD) and end stage renal disease. To this end\, he has been the principal investigator on several investigator-initiated grant-funded studies in this area. He has over 50 peer reviewed publications\, and serves on the editorial board of BMC Nephrology. \n\n \n \n\n\nDr Shayan Shirazian is a paid consultant of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC). Dr Andrea Mohindra is an employee of OPDC. \n\n\n\n\n\n \n Registration URL:https://nephu.org/event/understanding-polycystic-kidney-disease-an-overview-of-pkd-2262024-firstsession/ LOCATION:Maggiano’s Little Italy\, 70 Riverside Square Mall\, Hackensack\, NJ\, 07601\, United States CATEGORIES:Live Event ATTACH;FMTTYPE=image/jpeg:https://nephu.org/wp-content/uploads/2023/06/metabolic-acidosis_resize.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Barbados:20231214T180000 DTEND;TZID=America/Barbados:20231214T203000 DTSTAMP:20260718T113030 CREATED:20231201T155027Z LAST-MODIFIED:20240202T184458Z UID:10000888-1702576800-1702585800@nephu.org SUMMARY:Autosomal Dominant Polycystic Kidney Disease: The Role of Imaging in Diagnosis and Prognosis DESCRIPTION:About This Event\n \n \n \n \n \n \n \n \n \n \n IgA Nephropathy: Early Signs & Symptoms\, Disease Burden\, & Management\n Radiologists play a key role on the kidney care team in assisting in the diagnosis and prognosis of patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD). Measuring Total Kidney Volume (TKV) is currently the best biomarker for staging and predicting disease progression. In this presentation\, we will discuss the important role of imaging in diagnosis and prognosis of ADPKD\, explore different imaging modalities for measuring TKV\, including new automated methods\, review the use of imaging to assess ADPKD complications\, and discuss methods to facilitate successful communication between nephrologists and radiologists. \n \n\n\n\n\n\n\n \n Location\n \n \n\n\n\n\n\n\n\n\nFeaturing\n\n\n\n \n \n \n Josh Gariboldi\, PharmD\, BCPS\n Nephrology Senior Medical Science Liaison\n \n \n \n \n Otsuka Pharmaceutical Development & Commercialization\, Inc.* \n \n Josh Gariboldi\, PharmD\, BCPS joined Otsuka in January 2021 and is a Senior Medical Science Liaison on our Nephrology East Team\, covering the Carolinas and Tennessee. Dr Gariboldi earned his Doctor of Pharmacy degree from the University of Florida in 2012. He has more than eight years of experience as a clinical pharmacist in both the community and hospital settings\, most recently at Bon Secours Mercy Health St. Francis Hospital in Greenville\, SC. Dr Gariboldi served as a preceptor with Presbyterian College School of Pharmacy\, where he instructed students on Advanced Pharmacy Practice rotations. He holds board certifications in both pharmacotherapy and medical affairs. \n\n \n \n\n\nDr Josh Gariboldi is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n \n Registration URL:https://nephu.org/event/autosomal-dominant-polycystic-kidney-disease-the-role-of-imaging-in-diagnosis-and-prognosis-12142023-firstsession/ LOCATION:Huellas by Capriccio\, Carretera 107 km 2.9 Bo. Borinquen\, Aguadilla\, 00603\, Puerto Rico CATEGORIES:Live Event ATTACH;FMTTYPE=image/jpeg:https://nephu.org/wp-content/uploads/2022/12/IgAN-Overview-podcast_resize.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20231024T180000 DTEND;TZID=America/New_York:20231024T200000 DTSTAMP:20260718T113030 CREATED:20230914T022359Z LAST-MODIFIED:20231024T174549Z UID:10000867-1698170400-1698177600@nephu.org SUMMARY:Genetic Testing in Autosomal Dominant Polycystic Kidney Disease (ADPKD) DESCRIPTION:About This Event\n \n \n \n \n \n \n \n \n \n \n IgA Nephropathy: Early Signs & Symptoms\, Disease Burden\, & Management\n In this presentation\, the complexities of genetic testing in ADPKD\, recommendations on when genetic testing is appropriate and indicated\, and the various types of molecular genetic tests available will be discussed. \n \n\n\n\n\n\n\n \n Location\n \n \n\n\n\n\n\n\n\n\nFeaturing\n\n\n\n\n\n*Josh Gariboldi is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC) \n\n\n\n\n\n \n Registration URL:https://nephu.org/event/genetic-testing-in-autosomal-dominant-polycystic-kidney-disease-adpkd-102423-first-session/ LOCATION:The Establishment\, 28 Broad St\, Charleston\, SC\, 29401\, United States CATEGORIES:Live Event ATTACH;FMTTYPE=image/jpeg:https://nephu.org/wp-content/uploads/2023/08/live-event-1_resize.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Mexico_City:20230725T183000 DTEND;TZID=America/Mexico_City:20230725T210000 DTSTAMP:20260718T113030 CREATED:20230611T051451Z LAST-MODIFIED:20230825T213508Z UID:10000836-1690309800-1690318800@nephu.org SUMMARY:Increasing Awareness Of Autosomal Dominant Polycystic Kidney Disease (ADPKD) In Underrepresented & Underserved Communities DESCRIPTION:About This Event\n \n \n \n \n \n \n \n \n \n \n IgA Nephropathy: Early Signs & Symptoms\, Disease Burden\, & Management\n This presentation focuses on the impact of kidney disease and autosomal dominant polycystic kidney disease (ADPKD) in Black and Hispanic/Latino communities and the effects of social determinants of health on patients living with kidney. Diagnosing and managing the care of patients living with ADPKD will also be discussed. \n \n\n\n \n\n\n\n \n Location\n \n \n\n\n\n\n \n\n\n\n \n Featured Speakers\n \n \n\n\n\n\n\n\n*Dr Workeneh is a paid consultant of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC). Dr Lambert is an employee of OPDC. \n\n\n\n\n\n \n Registration URL:https://nephu.org/event/increasing-awareness-of-autosomal-dominant-polycystic-kidney-disease-adpkd-in-underrepresented-amp-underserved-communities-07252023-first-session/ LOCATION:Commander’s Palace\, 1403 Washington Ave\, New Orleans\, Louisiana\, 70130\, United States CATEGORIES:Live Event ATTACH;FMTTYPE=image/jpeg:https://nephu.org/wp-content/uploads/2020/10/Hospital-Meeting_resize.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20221013T180000 DTEND;TZID=America/New_York:20221013T200000 DTSTAMP:20260718T113030 CREATED:20220916T230048Z LAST-MODIFIED:20220916T230113Z UID:10000774-1665684000-1665691200@nephu.org SUMMARY:Overview Of Autosomal Dominant Polycystic Kidney Disease (ADPKD) DESCRIPTION:About This Event\n \n \n \n \n \n \n \n \n \n \n IgA Nephropathy: Early Signs & Symptoms\, Disease Burden\, & Management\n This presentation will discuss the pathophysiology\, disease progression\, and the physical & emotional burden of autosomal dominant polycystic kidney disease (ADPKD). The key factors that play into ADPKD disease diagnosis and progression will be presented. \n \n\n\n\n\n\n\n \n Location\n \n \n\n\n\n\n\n\n\n\n \n Featured Speakers\n \n \n\n\n\n\n\n\n*Dr Dahl is a paid consultant of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC). Dr Green is an employee of OPDC. \n\n\n\n\n\n \n Registration URL:https://nephu.org/event/overview-of-autosomal-dominant-polycystic-kidney-disease-adpkd-10132022-first-session/ LOCATION:Mitchell’s Steakhouse – Polaris\, 1408 Polaris Pkwy\, Columbus\, Ohio\, 43240\, United States CATEGORIES:Live Event ATTACH;FMTTYPE=image/png:https://nephu.org/wp-content/uploads/2020/06/Doctors-Writing-on-Charts-in-a-Meeting.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Phoenix:20220915T183000 DTEND;TZID=America/Phoenix:20220915T210000 DTSTAMP:20260718T113030 CREATED:20220825T014856Z LAST-MODIFIED:20220825T015146Z UID:10000671-1663266600-1663275600@nephu.org SUMMARY:Overview Of Autosomal Dominant Polycystic Kidney Disease (ADPKD) DESCRIPTION:About This Event\n \n \n \n \n \n \n \n \n \n \n IgA Nephropathy: Early Signs & Symptoms\, Disease Burden\, & Management\n This presentation will discuss the pathophysiology\, disease progression\, and the physical & emotional burden of autosomal dominant polycystic kidney disease (ADPKD). The key factors that play into ADPKD disease diagnosis and progression will be presented. \n \n\n\n\n\n\n\n \n Location\n \n \n\n\n\n\n\n\n\n\n \n Featured Speaker\n \n \n\n\n\n\n*Dr Hajarnis is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC). \n\n\n\n\n\n \n Registration URL:https://nephu.org/event/overview-of-autosomal-dominant-polycystic-kidney-disease-adpkd-09152022-second-session/ LOCATION:Seasons 52\, 6600 Menaul Blvd Pad 2\, Albuquerque\, New Mexico\, 87110\, United States CATEGORIES:Live Event ATTACH;FMTTYPE=image/png:https://nephu.org/wp-content/uploads/2020/06/Doctors-Writing-on-Charts-in-a-Meeting.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20220712T183000 DTEND;TZID=America/Los_Angeles:20220712T203000 DTSTAMP:20260718T113030 CREATED:20220521T014853Z LAST-MODIFIED:20220523T180703Z UID:10000751-1657650600-1657657800@nephu.org SUMMARY:Major Depressive Disorder (MDD) In Chronic Kidney Disease (CKD) DESCRIPTION:About This Event\n \n \n \n \n \n \n \n \n \n \n IgA Nephropathy: Early Signs & Symptoms\, Disease Burden\, & Management\n Major depressive disorder affects more than 260 million people worldwide.1 The reported prevalence of depression in patients with chronic kidney disease ranges from 20-65%.2 This presentation provides an overview of both MDD and CKD and discusses their overlap of symptomology. \n\n1. World Health Organization. Fact Sheet on Depression. (2012) https://www.who.int/health-topics/depression#tab=tab_1 \n\n2. Teles F et al. Clinics (Sao Paulo). 2014 ;69(3):198-202. \n \n\n\n\n\n\n\n \n Location\n \n \n\n\n\n\n\n\n\n\n \n Featured Speakers\n \n \n\n\n\n\n\n\n*Drs Somkuwar and Dallal are employees of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC). \n\n\n\n\n\n \n Registration URL:https://nephu.org/event/major-depressive-disorder-mdd-in-chronic-kidney-disease-ckd-07122022-first-session/ LOCATION:Eight4Nine\, 849 North Palm Canyon Drive\, Palm Springs\, California\, 92262 CATEGORIES:Live Event ATTACH;FMTTYPE=image/jpeg:https://nephu.org/wp-content/uploads/2021/09/medical-assessment_resize.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20220608T180000 DTEND;TZID=America/New_York:20220608T200000 DTSTAMP:20260718T113030 CREATED:20220510T161640Z LAST-MODIFIED:20220624T202132Z UID:10000747-1654711200-1654718400@nephu.org SUMMARY:Overview Of Autosomal Dominant Polycystic Kidney Disease (ADPKD) DESCRIPTION:About This Event\n \n \n \n \n \n \n \n \n \n \n IgA Nephropathy: Early Signs & Symptoms\, Disease Burden\, & Management\n This presentation will discuss the pathophysiology\, disease progression\, and the physical & emotional burden of autosomal dominant polycystic kidney disease (ADPKD). The key factors that play into ADPKD disease diagnosis and progression will be presented. \n \n\n\n\n\n\n\n \n Location\n \n \n\n\n\n\n\n\n\n\n \n Featured Speakers\n \n \n\n\n\n\n\n\n*Drs Green & Lockwood are employees of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC). \n\n\n\n\n\n \n Registration URL:https://nephu.org/event/overview-of-autosomal-dominant-polycystic-kidney-disease-adpkd-06082022-first-session/ LOCATION:Rockwell’s | Ottowa Room\, 27 Broadway\, Toledo\, Ohio\, 43604\, United States CATEGORIES:Live Event ATTACH;FMTTYPE=image/png:https://nephu.org/wp-content/uploads/2020/06/Doctors-Writing-on-Charts-in-a-Meeting.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20220519T180000 DTEND;TZID=America/Los_Angeles:20220519T200000 DTSTAMP:20260718T113030 CREATED:20220504T164401Z LAST-MODIFIED:20220625T032217Z UID:10000744-1652983200-1652990400@nephu.org SUMMARY:Nutritional Management In Chronic Kidney Disease: Importance Of Calories\, Protein & Fiber DESCRIPTION:About This Event\n \n \n \n \n \n \n \n \n \n \n IgA Nephropathy: Early Signs & Symptoms\, Disease Burden\, & Management\n This presentation discusses goals & aims of the 2020 National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) Clinical Practice Guidelines (CPGs) and nutrition recommendations for calories (energy)\, protein\, and fiber for patients with Kidney Disease. This presentation will underscore the critical role of nutrition/diet interventions to slow CKD progression\, avoid or delay end-stage kidney disease transition\, and improve patient outcomes. \n \n\n\n\n\n\n\n \n Location\n \n \n\n\n\n\n\n\n\n\n \n Featured Speaker\n \n \n\n\n\n\n*Dr Jansen is an employee of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC). \n\n\n\n\n\n \n Registration URL:https://nephu.org/event/nutritional-management-in-chronic-kidney-disease-importance-of-calories-protein-fiber-05192022-first-session/ LOCATION:Piatti\, 2695 Northeast Village Lane\, Seattle\, Washington\, 98105\, United States CATEGORIES:Live Event ATTACH;FMTTYPE=image/jpeg:https://nephu.org/wp-content/uploads/2021/12/ketogenic-diet-part-3_resize.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Denver:20220302T183000 DTEND;TZID=America/Denver:20220302T210000 DTSTAMP:20260718T113030 CREATED:20220211T002354Z LAST-MODIFIED:20220304T171033Z UID:10000629-1646245800-1646254800@nephu.org SUMMARY:Empowering Patients Through Health Literacy DESCRIPTION:This presentation brings you concepts and resources to help improve health literacy among your patients\, especially those with chronic kidney disease\, as they manage the complexities of their care regimen. Health literacy is crucial for dialysis and transplant patients so they can be empowered to participate in shared decision-making. Effective communication strategies lead to better patient engagement\, and engaged patients can better deal with the many challenges they face in living with kidney disease. \n\n\n\n*Drs Lambert and Hajarnis are employees of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC). \n\n\n\n You must be logged in to register for this event.\nPlease Log In or Join Now\n \n Join To View\n Already A Member? Login\n \n \n\n\n\n\nFeatured Speakers\n\n\n\n\n\n\n\nLocation: URL:https://nephu.org/event/empowering-patients-through-health-literacy-03022022-session/ LOCATION:Maggiano’s Little Italy Denver\, 500 16th St.\, Suite 150\, Denver\, Colorado\, 80202\, United States CATEGORIES:Live Event ATTACH;FMTTYPE=image/png:https://nephu.org/wp-content/uploads/2020/06/Group-of-doctors-in-a-circle-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/New_York:20220215T114500 DTEND;TZID=America/New_York:20220215T130000 DTSTAMP:20260718T113030 CREATED:20220126T211439Z LAST-MODIFIED:20220304T171229Z UID:10000726-1644925500-1644930000@nephu.org SUMMARY:Major Depressive Disorder In Chronic Kidney Disease DESCRIPTION:Sponsored By PsychU & NephU\n\n\n\nLimited Space Available \n\n\n\nThere is a high prevalence of depression among patients with chronic kidney disease (CKD). This presentation will examine the clinical overlap between CKD and major depressive disorder (MDD) in symptomatology\, behavioral and biological mechanisms\, the impact of comorbid depression on CKD outcomes\, and strategies for effective management of depression in CKD. \n\n\n\n*Drs Fornal & Emmel are employees of Otsuka Pharmaceutical Development & Commercialization\, Inc. (OPDC). \n\n\n\n You must be logged in to register for this event.\nPlease Log In or Join Now\n \n Join To View\n Already A Member? Login\n \n \n\n\n\n\nFeatured Speakers\n\n\n\n\n\n\n\nLocation: URL:https://nephu.org/event/major-depressive-disorder-in-chronic-kidney-disease-pmi-2022/ LOCATION:Sheraton Sand Key Resort – Clearwater Beach\, 1160 Gulf Blvd\, Clearwater Beach\, 33767\, United States CATEGORIES:Live Event ATTACH;FMTTYPE=image/png:https://nephu.org/wp-content/uploads/2020/06/Doctors-Writing-on-Charts-in-a-Meeting.png END:VEVENT END:VCALENDAR